Tetanus immune globulin
Tetanus immune globulin is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| tetanus | EFO_0005593 | D013742 | A35 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J1670 | Injection, tetanus immune globulin, human, up to 250 units |
Clinical
Clinical Trials
441 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypogonadism | D007006 | E23.0 | 22 | 42 | 32 | 36 | 15 | 141 | |
| Eunuchism | D005058 | EFO_0007266 | E29.1 | 4 | 8 | 10 | 9 | 3 | 34 |
| Healthy volunteers/patients | — | 10 | 4 | 2 | 2 | 3 | 19 | ||
| Psychological sexual dysfunctions | D020018 | F52.0 | 1 | 2 | 12 | 1 | 1 | 17 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | 3 | 1 | 3 | 3 | 11 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | 3 | 2 | 4 | 1 | 10 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | 1 | 1 | 6 | 1 | 10 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | 2 | 3 | 3 | 3 | 1 | 10 |
| Aging | D000375 | GO_0007568 | R41.81 | 4 | 2 | 1 | 1 | 2 | 10 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 3 | — | 6 | — | 9 |
Show 37 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | 5 | 12 | 1 | — | 4 | 22 | |
| Spinal cord injuries | D013119 | EFO_1001919 | 1 | 7 | 2 | — | — | 7 | |
| Infertility | D007246 | EFO_0000545 | 2 | 1 | 2 | — | 2 | 6 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 3 | 1 | — | 1 | 6 |
| Menopause | D008593 | EFO_0003922 | N95 | — | 4 | 1 | — | 1 | 6 |
| Transsexualism | D014189 | F64.0 | — | — | 2 | — | 2 | 4 | |
| Neoplasms | D009369 | C80 | — | 2 | 2 | — | — | 4 | |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | 1 | 2 | — | — | 3 |
| Physiological sexual dysfunction | D012735 | — | 1 | 1 | — | — | 2 | ||
| Testicular neoplasms | D013736 | C62 | — | 2 | 1 | — | — | 2 |
Show 21 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | 8 | 6 | — | — | — | 11 | ||
| Castration-resistant prostatic neoplasms | D064129 | 1 | 6 | — | — | — | 7 | ||
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 2 | 1 | — | — | 2 | 5 |
| Insulin resistance | D007333 | EFO_0002614 | 2 | 2 | — | — | 2 | 5 | |
| Androgen-insensitivity syndrome | D013734 | E34.5 | 1 | 3 | — | — | 1 | 4 | |
| Depression | D003863 | F33.9 | — | 2 | — | — | 2 | 4 | |
| Dyspareunia | D004414 | HP_0030016 | N94.1 | 2 | 1 | — | — | 1 | 3 |
| Gonadal disorders | D006058 | — | 2 | — | — | 1 | 3 | ||
| Cachexia | D002100 | HP_0004326 | R64 | 2 | 1 | — | — | — | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | 1 | 2 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Male infertility | D007248 | EFO_0004248 | N46 | 1 | — | — | — | 1 | 2 |
| Facioscapulohumeral muscular dystrophy | D020391 | EFO_0000491 | G71.02 | 1 | — | — | — | — | 1 |
| Cerebral arterial diseases | D002539 | EFO_1000859 | 1 | — | — | — | — | 1 | |
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Breast density | D000071060 | 1 | — | — | — | — | 1 | ||
| Postmenopause | D017698 | 1 | — | — | — | — | 1 | ||
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
| Priapism | D011317 | HP_0200023 | N48.3 | 1 | — | — | — | — | 1 |
| Virilism | D014770 | 1 | — | — | — | — | 1 | ||
| Squamous cell neoplasms | D018307 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 2 | 2 |
| Delayed puberty | D011628 | HP_0000823 | E30.0 | — | — | — | — | 2 | 2 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | — | 1 | 1 |
| Thalassemia | D013789 | EFO_1001996 | D56 | — | — | — | — | 1 | 1 |
| Stress urinary incontinence | D014550 | HP_0010992 | — | — | — | — | 1 | 1 | |
| Hysterectomy | D007044 | EFO_0003881 | — | — | — | — | 1 | 1 | |
| Ovariectomy | D010052 | — | — | — | — | 1 | 1 | ||
| Precocious puberty | D011629 | E22.8 | — | — | — | — | 1 | 1 | |
| Duchenne muscular dystrophy | D020388 | — | — | — | — | 1 | 1 | ||
| Paraplegia | D010264 | HP_0001258 | G82.2 | — | — | — | — | 1 | 1 |
Show 27 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TETANUS IMMUNE GLOBULIN |
| INN | — |
| Description | Anti-tetanus immunoglobulin, also known as tetanus immune globulin (TIG) and tetanus antitoxin, is a medication made up of antibodies against the tetanus toxin. It is used to prevent tetanus in those who have a wound that is at high risk and have not been fully vaccinated with tetanus toxoid. It is also used to treat tetanus along with antibiotics and muscle relaxants. It is given by injection into a muscle.
|
| Classification | Protein |
| Drug class | antineoplastics (mitotic inhibitors; tubulin binders) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201582 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 178 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
35,815 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more